Low expression identifies a subset of breast cancers with favorable prognosis and sensitivity to IGF-1 receptor targeting with ganitumab: Data from I-SPY2 and SCAN-B

Christopher Godina,Michael N Pollak,Helena Jernström

DOI: https://doi.org/10.1101/2023.12.18.23300129

2024-03-11

Abstract:There has been a long-standing interest in targeting the insulin-like growth factor-1 receptor (IGF-1R) signaling system in breast cancer due to its key role in neoplastic proliferation and survival. However, no IGF-1R targeting agent has shown substantial clinical benefit in controlled trials, and no treatment predictive biomarkers for IGF-1R targeting agents exist. IGFBP7 is an atypical insulin-like growth factor binding protein as it has a higher affinity for the IGF-1R than IGF ligands. We report that low gene expression identifies a subset of breast cancers for which the addition of ganitumab (an anti-IGF-1R monoclonal antibody) to chemotherapy substantially improved the pathological complete response rate compared to neoadjuvant chemotherapy alone. Furthermore, high expression predicted increased distant metastasis risk. If our findings are confirmed, decisions to halt the development of IGF-1 targeting drugs, which were based on disappointing results of prior trials that did not use predictive biomarkers, should be reviewed.

Oncology

What problem does this paper attempt to address?

The paper attempts to address whether the drug ganitumab, which targets the insulin-like growth factor-1 receptor (IGF-1R), can improve the pathological complete response rate (pCR) when combined with chemotherapy in breast cancer treatment, and to identify predictive biomarkers associated with IGF-1R targeted therapy.

Specifically, the study found that breast cancer patients with low expression of the IGFBP7 gene had a significantly higher pathological complete response rate when receiving adjuvant therapy with ganitumab combined with chemotherapy. In contrast, high expression of IGFBP7 indicated a higher risk of distant metastasis. If these findings are confirmed, the previous decision to halt the development of IGF-1 targeted drugs based on trial results that did not use predictive biomarkers should be reconsidered. Additionally, the study explored the relationship between IGFBP7 expression and breast cancer molecular subtypes and tumor microenvironment, and validated its effectiveness as a predictive biomarker.